FDA recall, , Moderate risk
American National Red Cross Apheresis Red Blood Cells
Apheresis Red Blood Cells, Leukocytes Reduced were misbranded when distributed.
Recall ended Sep 28, 2026. Still check yours.
Summary by Recall Canary from the FDA notice
What happened
The American National Red Cross, Lewis and Clark Region, began a recall of Apheresis Red Blood Cells, Leukocytes Reduced on October 6, 2025, because the product was misbranded when distributed. The FDA classified the recall and added it to the Enforcement Report on September 28, 2026, with the weekly report on October 7, 2026. The product was distributed in Nevada and Utah.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Compare these details with yours, then check the recall notice to see which units are recalled.
Apheresis Red Blood Cells, Leukocytes Reduced
Recall details
- Company began the recall
- Company
- American National Red Cross (The), Lewis and Clark Region
- Hazard
- Mislabeled product
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99740
- Recall number
- B-0227-2026
All recalls from American National Red Cross (The), Lewis and Clark Region
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA · Recall ended
In FDA's weekly enforcement report
Listed on Recall Canary
